Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of Hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of Hyperuricemia through several mechanisms. This trial aims to examine its protective effect in humans.
Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids. However, whether administration of prebiotics also has a protective effect in subjects with Hyperuricemia remain unknown.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
120
During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
Department of Nutrition and Food Hygiene
Guangzhou, Guangdong, China
RECRUITINGSun Yat-Sen University
Guangzhou, Guangdong, China
RECRUITINGChange of serum Uric acid
change of fasting uric acid level assessed by biochemical detector
Time frame: from baseline to 12 weeks after intervention
Change of excretion of uric acid
excretion rate of uric acid assessed by secretion rate of uric acid in urine during 3 hours
Time frame: from baseline to 12 weeks after intervention
Change of Gut microbiota
Alterations of the composition of gut microbiota evaluated by metagenomics
Time frame: from baseline to 12 weeks after intervention
Change of Microbial metabolites
Untargeted metabolomics will be used to assess the alterations of microbial metabolites with High performance liquid chromatography-mass spectrometry
Time frame: from baseline to 12 weeks after intervention
Change in blood pressure
Change in blood pressure assessed by electronic sphygmomanometer
Time frame: from baseline to 12 weeks after intervention
Change in fasting glucose
Change in fasting glucose assessed by biochemical detector
Time frame: from baseline to 12 weeks after intervention
Change in waist circumference
Change in waist circumference assessed by tape
Time frame: from baseline to 12 weeks after intervention
Change in lipid profiles
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in total cholesterol, triglycerides, LDL-c and HDL-c assessed by biochemical detector
Time frame: from baseline to 12 weeks after intervention